NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-NS-24-014 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIH Blueprint R25 program is to encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical, behavioral, and clinical research workforce, to pursue further studies or careers in research. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development, Research Experiences, and Mentoring Activities.The fully integrated educational activities should prepare undergraduate students from diverse backgrounds, including those from groups underrepresented in biomedical and behavioral sciences to enter Ph.D. degree programs in the neurosciences. To accomplish this goal, this initiative will provide institutional awards to develop neuroscience research education programs comprised of collaborative partnerships integrated across different educational institution types. Each partnership must include: a) one or more institutions that either: 1) have a historical and current mission to educate students from any of the populations that have been identified as underrepresented in biomedical research as defined by the National Science Foundation NSF, see http://www.nsf.gov/statistics/wmpd/) (i.e., African Americans or Blacks, Hispanic or Latino Americans, American Indians, Alaska Natives, Native Hawaiians, U.S. Pacific Islanders, and persons with disabilities) or 2) have a documented track record of recruiting, training and/or educating, and graduating underrepresented students as defined by NSF (see above), which has resulted in increasing the institution's contribution to the national pool of graduates from underrepresented backgrounds who pursue biomedical research careers; b) a research-intensive institution that has an established neuroscience or neuroscience-related program; c) integrated
Notice NOT-AT-24-011 from the NIH Guide for Grants and Contracts
Notice NOT-HL-23-100 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-23-246 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages applications promoting transformative discoveries in cancer biology and/or oncology through the use of nanotechnology. Proposed projects should address major barriers in cancer biology and/or oncology using nanotechnology and should emphasize mechanistic studies toward fundamental understanding of nanomaterial and/or nanodevice interactions with biological systems. These studies should be performed in context of research concerning the delivery of nanoparticles and/or nano-devices to desired and intended cancer targets in vivo and/or characterization of detection and diagnostic devices in vitro. IRCN awards are expected to produce fundamental knowledge to aid future and more informed development of nanotechnology-based cancer interventions. The clinical translation of these interventions is outside of the scope of this NOFO.
Notice NOT-GM-23-050 from the NIH Guide for Grants and Contracts
Notice NOT-MH-23-365 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AT-24-004 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is to solicit UG3/UH3 phased cooperative agreement research applications to conduct efficient, large-scale pragmatic clinical trial and/or implementation science Demonstration Projects within the infrastructure of the NIH-DoD-VA Pain Management Collaboratory (PMC) on nonpharmacologic approaches to pain management and other comorbid conditions in U.S. veterans, military personnel, and their families. The PMC established a Coordinating Center that provides national leadership and technical expertise for all aspects of health care system (HCS)-focused research including assistance to UG3/UH3 grant awardees.
Funding Opportunity RFA-HL-24-009 from the NIH Guide for Grants and Contracts. This NOFO will support preliminary studies aimed to obtain information necessary to guide the design of a full randomized control trial to test whether sleep and circadian targeted interventions improve the clinical course and treatment outcomes in individuals with Type 1 Diabetes (T1D). Applications should focus on pilot studies to inform practical and potentially sustainable strategies to improve processes of care and cardiometabolic health outcomes in individuals with T1D. The scope of research for this NOFO includes a range of feasibility metrics (e.g., optimizing recruitment, retention, randomization); intervention logistics (e.g., determine independent variable(s), dose-response, duration); study design/statistical considerations (e.g., determination of effect size, sample size, and statistical power; inclusion/exclusion criteria, control variables); adherence outcomes (measures of patient acceptance of, satisfaction with, and adherence to treatment); assessment of intermediate markers of the intervention (e.g. glycemic control, vascular dysfunction, inflammation, and/or neuroendocrine and metabolic function); and selection of primary and/or secondary outcome(s) measures. Ultimately, results from these pilot studies will be used to develop a well-powered, evidence-based definitive clinical trial that could improve clinical care and cardiometabolic outcomes in individuals with T1D and to inform guidelines for this patient population. Transdisciplinary investigative teams including relevant expertise in sleep/circadian, T1D and cardiovascular research, as well as needed expertise in clinical trial design, biostatistics and other appropriate areas are encouraged. Studies should include active participation of children, adolescents, and/or adults with T1D. This program is not intended to develop or validate new treatments of devices for sleep and/or circadian deficiency. Animal studies will not be considered responsive to this initiative.
Funding Opportunity RFA-HL-24-008 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is to elucidate the contribution of sleep deficiency and circadian disruption to metabolic and cardiovascular pathobiology, disease trajectory, and treatment response in individuals living with Type 1 Diabetes (T1D). The RFA will support clinically relevant, mechanism focused research on the interface between sleep, circadian rhythms biology, T1D and cardiovascular disease. Multi-disciplinary teams bridging sleep/circadian, diabetes, and cardiovascular research are encouraged. Proposed research should be relevant to the ultimate goal of applying sleep and circadian strategies to improve treatment and outcomes in individuals with T1D, and to mitigate related cardiovascular complications. Observational studies, epidemiology, efficacy trials and basic animal research will not be responsive to this NOFO.
Notice NOT-HD-23-020 from the NIH Guide for Grants and Contracts
Notice NOT-HD-23-023 from the NIH Guide for Grants and Contracts
Notice NOT-HD-23-022 from the NIH Guide for Grants and Contracts
Notice NOT-AG-23-042 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-24-063 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support research focusing on the identification of druggable new targets and discovery of optimizable probes for development of safe and efficacious medications to prevent and treat opioid use disorders (OUDs), opioid overdose, and opioid-polysubstance use comorbidities. This notice of funding opportunity is part of the NIH Helping to End Addictions Long-term (HEAL) initiative to accelerate the development of novel medications to treat all aspects of the opioid addiction cycle, including progression to chronic use, withdrawal symptoms, craving, relapse, and overdose.
Funding Opportunity RFA-DA-24-064 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support research focusing on the identification of druggable new targets and discovery of optimizable probes for development of safe and efficacious medications to prevent and treat opioid use disorders (OUDs), opioid overdose, and opioid-polysubstance use comorbidities. This notice of funding opportunity is part of the NIH Helping to End Addictions Long-term (HEAL) initiative to accelerate the development of novel medications to treat all aspects of the opioid addiction cycle, including progression to chronic use, withdrawal symptoms, craving, relapse, and overdose.
Funding Opportunity RFA-AG-24-050 from the NIH Guide for Grants and Contracts. This NOFO invites R61/R33 applications that address health equity, drug costs, and access to new therapeutics or repurposed drugs for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Successful applications will seek to identify preferences for pharmacological treatment among racial and ethnic minority people living with AD/ADRD, assess whether cost barriers to pharmacological care exist for racial and ethnic minority people living with AD/ADRD, and quantify expenditures and health- related quality of life (HRQoL) among people interested in receiving novel or repurposed drugs for AD/ADRD. This NOFO will support a study development phase (R61) to conduct rigorous stakeholder engagement with racial and ethnic minority groups to identify, measure, and assess the demand for new and repurposed drugs, and if successful, grantees will transition to an R33 phase for implementation of rigorous modeling of costs and health-related quality of life and dissemination of model findings.
Funding Opportunity RFA-DA-25-014 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity announcement is to generate brain region and cell-type specific microglial protein profiles in the context of HIV and SUD, then use those molecular profiles and interaction networks to establish mechanisms of how HIV-harboring microglia may contribute specifically to neuropathologies encountered with comorbid HIV and SUD.
Funding Opportunity PAR-23-239 from the NIH Guide for Grants and Contracts. This initiative seeks to solicit applications for research projects that address the link between social disconnection including both objective social isolation as well as perceived social isolation (otherwise known as loneliness) and suicide in late-life. Emphasis is placed on research that identifies neurobiological and environmental mechanisms associated with social isolation and loneliness that increase risk for suicidal thoughts and behavior in late-life, that uses an experimental therapeutics approach to identify targets and develop and test interventions to prevent late-life suicide, and that develops new and modifies existing service delivery models to enhance social connection in late-life to prevent suicide.
Funding Opportunity PAR-23-238 from the NIH Guide for Grants and Contracts. This initiative seeks to solicit applications for research projects that address the link between social disconnection including both objective social isolation as well as perceived social isolation (otherwise known as loneliness) and suicide in late-life. Emphasis is placed on research that identifies neurobiological and environmental mechanisms associated with social isolation and loneliness that increase risk for suicidal thoughts and behavior in late-life, that uses an experimental therapeutics approach to identify targets and develop and test interventions to prevent late-life suicide, and that develops new and modifies existing service delivery models to enhance social connection in late-life to prevent suicide.
Notice NOT-MD-23-016 from the NIH Guide for Grants and Contracts